Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study.

Abrahami D, Douros A, Yin H, Yu OH, Faillie JL, Montastruc F, Platt RW, Bouganim N, Azoulay L.

BMJ. 2018 Dec 5;363:k4880. doi: 10.1136/bmj.k4880.

2.

Programmed Cell Death Ligand 1-Induced Coma From Diffuse Cerebritis.

Desforges P, Esfahani K, Bouganim N.

J Oncol Pract. 2018 Feb;14(2):134-135. doi: 10.1200/JOP.2017.024992. Epub 2017 Oct 10. No abstract available.

PMID:
29016224
3.

The use of drugs acting on the renin-angiotensin system and the incidence of pancreatic cancer.

Mandilaras V, Bouganim N, Yin H, Asselah J, Azoulay L.

Br J Cancer. 2017 Jan 3;116(1):103-108. doi: 10.1038/bjc.2016.375. Epub 2016 Nov 15.

4.

Use of Calcium Channel Blockers and Risk of Breast Cancer: A Population-based Cohort Study.

Azoulay L, Soldera S, Yin H, Bouganim N.

Epidemiology. 2016 Jul;27(4):594-601. doi: 10.1097/EDE.0000000000000483.

PMID:
27031042
5.

Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial.

Clemons M, Bouganim N, Smith S, Mazzarello S, Vandermeer L, Segal R, Dent S, Gertler S, Song X, Wheatley-Price P, Dranitsaris G.

JAMA Oncol. 2016 Feb;2(2):225-31. doi: 10.1001/jamaoncol.2015.3730.

PMID:
26562292
6.

Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors.

Dranitsaris G, Mazzarello S, Smith S, Vandermeer L, Bouganim N, Clemons M.

Support Care Cancer. 2016 Apr;24(4):1563-9. doi: 10.1007/s00520-015-2944-x. Epub 2015 Sep 17.

PMID:
26381427
7.

Erratum to: platinum-based chemotherapy in triple-negative advanced breast cancer.

Villarreal-Garza C, Khalaf D, Bouganim N, Clemons M, Peña-Curiel O, Baez-Revueltas B, Kiss A, Kassam F, Enright K, Verma S, Pritchard K, Myers J, Dent R.

Breast Cancer Res Treat. 2015 Apr;150(3):697. doi: 10.1007/s10549-015-3345-z. No abstract available.

PMID:
25809091
8.

A case of recurrent anaplastic meningioma of the skull base with radiologic response to hydroxyurea.

Gurberg J, Bouganim N, Shenouda G, Zeitouni A.

J Neurol Surg Rep. 2014 Aug;75(1):e52-5. doi: 10.1055/s-0033-1359300. Epub 2014 Apr 17.

9.

Cardiac glycosides and the risk of breast cancer in women with chronic heart failure and supraventricular arrhythmia.

Couraud S, Dell'Aniello S, Bouganim N, Azoulay L.

Breast Cancer Res Treat. 2014 Aug;146(3):619-26. doi: 10.1007/s10549-014-3058-8. Epub 2014 Jul 20.

PMID:
25038879
10.

Platinum-based chemotherapy in triple-negative advanced breast cancer.

Villarreal-Garza C, Khalaf D, Bouganim N, Clemons M, Peña-Curiel O, Baez-Revueltas B, Kiss A, Kassam F, Enright K, Verma S, Pritchard K, Myers J, Dent R.

Breast Cancer Res Treat. 2014 Aug;146(3):567-72. doi: 10.1007/s10549-014-3033-4. Epub 2014 Jul 8. Erratum in: Breast Cancer Res Treat. 2015 Apr;150(3):697.

PMID:
25001611
11.

A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.

Addison CL, Bouganim N, Hilton J, Vandermeer L, Dent S, Amir E, Hopkins S, Kuchuk I, Segal R, Song X, Gertler S, Mazzarello S, Dranitsaris G, Ooi D, Pond G, Clemons M.

Breast Cancer Res Treat. 2014 Apr;144(3):615-24. doi: 10.1007/s10549-014-2906-x. Epub 2014 Mar 18.

12.

Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression.

Khalaf D, Hilton JF, Clemons M, Azoulay L, Yin H, Vandermeer L, Dent S, Hopkins S, Bouganim N.

Oncol Lett. 2014 Mar;7(3):866-870. Epub 2014 Jan 7.

13.

Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects.

Beusterien K, Grinspan J, Kuchuk I, Mazzarello S, Dent S, Gertler S, Bouganim N, Vandermeer L, Clemons M.

Oncologist. 2014 Feb;19(2):127-34. doi: 10.1634/theoncologist.2013-0359. Epub 2014 Jan 28.

14.

De-escalated administration of bone-targeted agents in patients with breast and prostate cancer-A survey of Canadian oncologists.

Hutton B, Addison C, Mazzarello S, Joy AA, Bouganim N, Fergusson D, Clemons M.

J Bone Oncol. 2013 Apr 15;2(2):77-83. doi: 10.1016/j.jbo.2013.03.001. eCollection 2013 Jun.

15.

Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting.

Dranitsaris G, Bouganim N, Milano C, Vandermeer L, Dent S, Wheatley-Price P, Laporte J, Oxborough KA, Clemons M.

J Support Oncol. 2013 Mar;11(1):14-21.

PMID:
22763232
16.

Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists.

Bouganim N, Dranitsaris G, Amir E, Clemons M.

Support Care Cancer. 2011 Nov;19(11):1687-96. doi: 10.1007/s00520-011-1230-9. Epub 2011 Jul 22. Review.

PMID:
21785900
17.

More about osteonecrosis.

Finkelman RD, Clemons M, Bouganim N.

J Am Dent Assoc. 2011 Apr;142(4):371-2; author reply 372-4. No abstract available.

PMID:
21454842
18.

Bone-targeted agents in the treatment of bone metastases: RANK outsider or new kid on the block?

Bouganim N, Clemons MJ.

Future Oncol. 2011 Mar;7(3):381-3. doi: 10.2217/fon.10.192.

PMID:
21417901
19.

Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis.

Chaudhury P, Hassanain M, Bouganim N, Salman A, Kavan P, Metrakos P.

HPB (Oxford). 2010 Feb;12(1):37-42. doi: 10.1111/j.1477-2574.2009.00119.x.

20.

Mnemonics in dermatology.

Bouganim N, Barankin B, Freiman A.

Int J Dermatol. 2006 Jan;45(1):81-2. No abstract available.

PMID:
16426384
21.

History of cryotherapy.

Freiman A, Bouganim N.

Dermatol Online J. 2005 Aug 1;11(2):9.

22.

Aggressive fibromatosis of the head and neck: case report and review of the literature.

Abikhzer G, Bouganim N, Finesilver A.

J Otolaryngol. 2005 Aug;34(4):289-94. Review. No abstract available.

PMID:
16048709
23.

Case reports: mitozantrone-induced onycholysis associated with subungual abscesses, paronychia, and pyogenic granuloma.

Freiman A, Bouganim N, O'Brien EA.

J Drugs Dermatol. 2005 Jul-Aug;4(4):490-2.

PMID:
16004024
24.

Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.

Stagg J, Wu JH, Bouganim N, Galipeau J.

Cancer Res. 2004 Dec 15;64(24):8795-9.

Supplemental Content

Loading ...
Support Center